Recursion Pharmaceuticals, Inc. (RXRX) Revenue History
Annual and quarterly revenue from 2019 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
RXRX Revenue Growth
Revenue Breakdown (FY 2025)
RXRX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
RXRX Revenue Analysis (2019–2025)
As of May 8, 2026, Recursion Pharmaceuticals, Inc. (RXRX) generated trailing twelve-month (TTM) revenue of $66.3 million, reflecting significant decline in growth of -56.1% year-over-year. The most recent quarter (Q1 2026) recorded $6.5 million in revenue, down 81.8% sequentially.
Looking at the longer-term picture, RXRX's 5-year compound annual growth rate (CAGR) stands at +85.4%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $74.7 million in 2025, representing a new all-time high.
Revenue diversification analysis shows RXRX's business is primarily driven by License and Service (99%), and Grant (1%). With over half of revenue concentrated in License and Service, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including SDGR (+10.6% YoY), ABCL (+160.5% YoY), and RLAY (+39.0% YoY), RXRX has underperformed the peer group in terms of revenue growth. Compare RXRX vs SDGR →
RXRX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| RXRXCurrent | $66M | -56.1% | +85.4% | -867.9% | |
 SDGR | $256M | +10.6% | +18.8% | -65.2% | |
 ABCL | $75M | +160.5% | -20.3% | -289.0% | |
 RLAY | $15M | +39.0% | -28.6% | -1971.6% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% |
RXRX Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $74.7M | +26.9% | $-46,273,000 | -62.0% | $-648,132,000 | -867.9% |
| 2024 | $58.8M | +34.1% | $13.6M | 23.1% | $-479,004,000 | -814.1% |
| 2023 | $43.9M | +10.6% | $1.3M | 2.9% | $-350,060,000 | -797.8% |
| 2022 | $39.7M | +296.8% | $-8,594,000 | -21.7% | $-245,727,000 | -619.3% |
| 2021 | $10.0M | +193.0% | $10.0M | 100.0% | $-182,775,000 | -1827.8% |
| 2020 | $3.4M | +99.5% | $3.4M | 100.0% | $-84,615,000 | -2479.2% |
| 2019 | $1.7M | - | $-44,098,000 | -2577.3% | $-62,441,000 | -3649.4% |
See RXRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RXRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RXRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRXRX — Frequently Asked Questions
Quick answers to the most common questions about buying RXRX stock.
Is RXRX's revenue growth accelerating or slowing?
RXRX revenue declined -56.1% year-over-year, contrasting with the 5-year CAGR of +85.4%. TTM revenue fell to $66M. This reverses the prior growth trend.
What is RXRX's long-term revenue growth rate?
Recursion Pharmaceuticals, Inc.'s 5-year revenue CAGR of +85.4% reflects the variable expansion pattern. Current YoY growth of -56.1% is below this long-term average.
How is RXRX's revenue distributed by segment?
RXRX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2025 are available for download. Segment mix reveals concentration and diversification trends.